Renovare Therapeutics, Inc.
About Renovare Therapeutics, Inc.
Renovare Therapeutics, Inc. is a privately held biotechnology company formed in April 2026 in Boulder, CO, to commercialize regenerative therapies for osteoarthritis developed through academic research. The company emerged from stealth mode via a collaboration with the University of Colorado Boulder and focuses on therapies that repair cartilage and bone damage to address root causes of osteoarthritis rather than just symptoms. Its pipeline aims to halt or reverse disease progression and restore mobility. The company was built on 25+ years of tissue engineering research and is developing three core technologies.
- 🔗 Renovare Therapeutics: $33.5 Million ARPA-H Backed Biotech Launches To Advance Osteoarthritis Regenerative Therapies
- 🔗 Renovare Therapeutics Emerges from Stealth Mode with $33.5M ARPA-H Funding for Osteoarthritis Regenerative Therapies - MedPath Trial
- 🔗 Renovare Therapeutics Inc. | Venture Partners at CU Boulder | University of Colorado Boulder
- 🔗 Renovare Therapeutics — Regenerating Joints, Restoring Life
- 🔗 Insights | Wilson Sonsini
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Launched from stealth in April 2026 through CU Boulder collaboration.
- Secured access to up to $33.5M non-dilutive ARPA-H award for NITRO program.
- Developing regenerative therapies targeting cartilage and bone repair in osteoarthritis.
- Portfolio originated from 25+ years of academic research at CU Boulder, CU Anschutz, and CSU.
Ask StreetZero about Renovare Therapeutics, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account